NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ChemoCentryx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $44.99 +1.75 (+4.05 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$43.48Now: $44.99▼$45.5050-Day Range$32.73MA: $42.75▼$50.7852-Week Range$6.16Now: $44.99▼$51.36Volume565,333 shsAverage Volume686,786 shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/ABeta2.09 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.Read More Beat the Market (BTM) Rank™ 4.6 Analyst's Opinion Consensus RatingChemoCentryx has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.50, ChemoCentryx has a potential upside of 32.3% from its current price of $44.99.Amount of Analyst CoverageChemoCentryx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesChemoCentryx has received 293 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChemoCentryx has received 268 “underperform” votes. (Add your “underperform” vote.)Community SentimentChemoCentryx has received 52.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote “Outperform” if you believe CCXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChemoCentryx does not currently pay a dividend.Dividend GrowthChemoCentryx does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChemoCentryx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,617,220.00 in company stock.Percentage Held by InsidersOnly 12.20% of the stock of ChemoCentryx is held by insiders.Percentage Held by Institutions64.23% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChemoCentryx are expected to grow by 3.05% in the coming year, from ($1.31) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChemoCentryx is -46.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChemoCentryx is -46.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemoCentryx has a P/B Ratio of 39.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.76 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CCXI Previous Symbol CUSIP16383L10 CIK1340652 Webhttp://www.chemocentryx.com/ Phone650-210-2900Debt Debt-to-Equity Ratio0.30 Current Ratio2.95 Quick Ratio2.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.13 million Price / Sales76.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book39.46Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-55,490,000.00 Net Margins-153.59% Return on Equity-79.28% Return on Assets-24.87%Miscellaneous Employees76 Outstanding Shares61,645,000Market Cap$2.77 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive CCXI News and Ratings via Email Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CCXI Rates by TradingView ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions How has ChemoCentryx's stock been impacted by COVID-19 (Coronavirus)? ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 8.3% and is now trading at $44.99. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ChemoCentryx? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx. When is ChemoCentryx's next earnings date? ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for ChemoCentryx. How were ChemoCentryx's earnings last quarter? ChemoCentryx Inc (NASDAQ:CCXI) posted its earnings results on Tuesday, March, 10th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.26). The biopharmaceutical company had revenue of $10.05 million for the quarter, compared to analyst estimates of $9.42 million. ChemoCentryx had a negative return on equity of 79.28% and a negative net margin of 153.59%. View ChemoCentryx's earnings history. What price target have analysts set for CCXI? 6 equities research analysts have issued 12 month target prices for ChemoCentryx's shares. Their forecasts range from $54.00 to $64.00. On average, they expect ChemoCentryx's stock price to reach $59.50 in the next year. This suggests a possible upside of 32.3% from the stock's current price. View analysts' price targets for ChemoCentryx. Has ChemoCentryx been receiving favorable news coverage? Media headlines about CCXI stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ChemoCentryx earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutChemoCentryx. Are investors shorting ChemoCentryx? ChemoCentryx saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 2,200,000 shares, a decrease of 16.3% from the February 13th total of 2,630,000 shares. Based on an average trading volume of 638,700 shares, the short-interest ratio is currently 3.4 days. Currently, 5.5% of the shares of the stock are sold short. View ChemoCentryx's Current Options Chain. Who are some of ChemoCentryx's key competitors? Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of ChemoCentryx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Arrowhead Pharmaceuticals (ARWR), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), NVIDIA (NVDA), Gilead Sciences (GILD), Opko Health (OPK) and Sorrento Therapeutics (SRNE). Who are ChemoCentryx's key executives? ChemoCentryx's management team includes the following people: Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)Dr. Rajinder Singh, Sr. VP of Research (Age 52)Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58) What is ChemoCentryx's stock symbol? ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI." How do I buy shares of ChemoCentryx? Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ChemoCentryx's stock price today? One share of CCXI stock can currently be purchased for approximately $44.99. How big of a company is ChemoCentryx? ChemoCentryx has a market capitalization of $2.77 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe. View additional information about ChemoCentryx. What is ChemoCentryx's official website? The official website for ChemoCentryx is http://www.chemocentryx.com/. How can I contact ChemoCentryx? ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Does the Dogs of the Dow strategy work?
